The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives
Mammals expend energy in many ways, including basic cellular maintenance and repair,
digestion, thermoregulation, locomotion, growth and reproduction. These processes can …
digestion, thermoregulation, locomotion, growth and reproduction. These processes can …
Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease
Parkinson's disease (PD) is the second leading neurodegenerative disease globally,
impacting the quality of life of millions of people. It is estimated that the treatment cost of PD …
impacting the quality of life of millions of people. It is estimated that the treatment cost of PD …
Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson's disease
P Jenner, A Mori, SD Aradi… - Expert Review of …, 2021 - Taylor & Francis
Introduction It is now accepted that Parkinson's disease (PD) is not simply due to
dopaminergic dysfunction, and there is interest in develo** non-dopaminergic …
dopaminergic dysfunction, and there is interest in develo** non-dopaminergic …
Targeting adenosine A2A receptors in Parkinson's disease
MA Schwarzschild, L Agnati, K Fuxe, JF Chen… - Trends in …, 2006 - cell.com
The adenosine A 2A receptor has emerged as an attractive non-dopaminergic target in the
pursuit of improved therapy for Parkinson's disease (PD), based in part on its unique CNS …
pursuit of improved therapy for Parkinson's disease (PD), based in part on its unique CNS …
Dopamine, behavioral economics, and effort
There are numerous problems with the hypothesis that brain dopamine (DA) systems,
particularly in the nucleus accumbens, directly mediate the rewarding or primary …
particularly in the nucleus accumbens, directly mediate the rewarding or primary …
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
Several selective antagonists for adenosine A2A receptors (A2AR) are currently under
evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably …
evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably …
[HTML][HTML] Caffeine and selective adenosine receptor antagonists as new therapeutic tools for the motivational symptoms of depression
Major depressive disorder is one of the most common and debilitating psychiatric disorders.
Some of the motivational symptoms of depression, such anergia (lack of self-reported …
Some of the motivational symptoms of depression, such anergia (lack of self-reported …
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
K Xu, E Bastia, M Schwarzschild - Pharmacology & therapeutics, 2005 - Elsevier
In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
The psychopharmacology of effort-related decision making: dopamine, adenosine, and insights into the neurochemistry of motivation
Effort-based decision making is studied using tasks that offer choices between high-effort
options leading to more highly valued reinforcers versus low-effort/low-reward options …
options leading to more highly valued reinforcers versus low-effort/low-reward options …
Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms
RDS Prediger - Journal of Alzheimer's Disease, 2010 - content.iospress.com
Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting
approximately 1% of the population older than 60 years. Classically, PD is considered to be …
approximately 1% of the population older than 60 years. Classically, PD is considered to be …